Related posts
Nervous markets await NvidiaThis summary was created by AI, based on 3 opinions in the last 12 months.
Sanofi-Aventis (SNY) is gaining attention from analysts as a TOP PICK due to its recent performance and future potential. The company has shown impressive sales growth for three consecutive quarters, exceeding 10%, while managing its cash reserves prudently to reduce debt and buy back shares. Analysts highlight a favorable valuation, trading at 13-25 times earnings with strong return on equity (ROE) ranging from 25% to 27%. Despite a recent dip in the stock price due to weak earnings and the spin-off of its consumer healthcare operations, insights suggest that this decline could be a one-off event. Overall, experts are optimistic about the stock's potential to occupy a higher trading range moving forward.
SNY touched the bottom of its range in October 2023 on weak earnings and news that it would spin-off its consumer healthcare operations. The stock looks to be breaking out and while very hard to predict we think it is possible it trades in a higher new range. The drop last year was likely a one-off driven by the spin-off news, and barring a significant news item as such or consistently weak earnings, we would be surprised if it got back to the low-end of its range.
Unlock Premium - Try 5i Free
Sanofi-Aventis is a American stock, trading under the symbol SNY-N on the New York Stock Exchange (SNY). It is usually referred to as NYSE:SNY or SNY-N
In the last year, 1 stock analyst published opinions about SNY-N. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Sanofi-Aventis.
Sanofi-Aventis was recommended as a Top Pick by on . Read the latest stock experts ratings for Sanofi-Aventis.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
1 stock analyst on Stockchase covered Sanofi-Aventis In the last year. It is a trending stock that is worth watching.
On 2025-05-06, Sanofi-Aventis (SNY-N) stock closed at a price of $53.15.
We reiterate SNY as a TOP PICK. Recently reported earnings showed sales growth for the third consecutive quarter that exceeded 10%. Cash reserves are prudently being drawn down to retire debt and buy back shares. It trades at 13x earnings, 1.6x book and supports a 25% ROE. We recommend trailing up the stop (from $42) to $47, looking to achieve $64 -- upside potential of 20%. Yield 2.7%
(Analysts’ price target is $64.00)